Literature DB >> 18799875

Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation.

Takayuki Naya1, Kazushi Yukiiri, Naohisa Hosomi, Tsutomu Takahashi, Hiroyuki Ohkita, Mao Mukai, James A Koziol, Masakazu Kohno.   

Abstract

BACKGROUND: Cardioembolic stroke generally results in severer disability, since it typically has a larger ischemic area than the other types of ischemic stroke. However, it is difficult to differentiate cardioembolic from noncardioembolic stroke (atherothrombotic and lacunar stroke), whenever ischemic stroke patients have sinus rhythm at the time of presentation.
METHODS: In this study, we evaluated the levels of plasma brain natriuretic peptide in acute ischemic stroke patients with cardioembolic or noncardioembolic stroke and assessed whether this could provide a basis for differentiating cardioembolic stroke (especially due to paroxysmal atrial fibrillation) from noncardioembolic stroke. Our patient cohort consisted of 99 consecutive patients with acute cerebral infarction who were admitted to Kagawa University School of Medicine Hospital from January 1, 2005, to December 31, 2006. We excluded 23 patients with valve disease, heart failure, myocardial infarction or chronic renal failure. The mean age of the remaining 76 patients (51 males, 25 females) was 70.0 +/- 10.1 years.
RESULTS: Thirty-six patients had cardioembolic stroke with atrial fibrillation (including permanent and paroxysmal atrial fibrillation); the remaining 40 had noncardioembolic stroke. The plasma brain natriuretic peptide was evaluated on the first morning after admission in all patients. In cardioembolic stroke with atrial fibrillation (permanent and paroxysmal atrial fibrillation), the plasma brain natriuretic peptide, ratio of peak early filling velocity to peak atrial systolic velocity (E/A) and left atrial diameter were significantly increased (p < 0.001), and the left atrial appendage flow was significantly decreased (p < 0.001), compared with noncardioembolic stroke. Analyzed in those 4 factors, cardioembolic stroke was strongly predicted with >95% accuracy assessed by plasma brain natriuretic peptide and left atrial appendage flow.
CONCLUSION: From our results, it was suggested that the first-day brain natriuretic peptide and left atrial appendage flow measurements would be helpful in differentiating cardioembolic stroke with atrial fibrillation from noncardioembolic stroke. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799875     DOI: 10.1159/000155640

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  11 in total

1.  Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin.

Authors:  E Santamarina; A Penalba; T García-Berrocoso; P Delgado; M Quintana; T González-Alujas; M Ribó; O Maisterra; C A Molina; A Evangelista; J Alvarez-Sabín; J Montaner
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

2.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

3.  Brain natriuretic peptide predicts functional outcome in ischemic stroke.

Authors:  Natalia S Rost; Alessandro Biffi; Lisa Cloonan; John Chorba; Peter Kelly; David Greer; Patrick Ellinor; Karen L Furie
Journal:  Stroke       Date:  2011-11-23       Impact factor: 7.914

Review 4.  Left atrial appendage exclusion for atrial fibrillation.

Authors:  Faisal F Syed; Christopher V DeSimone; Paul A Friedman; Samuel J Asirvatham
Journal:  Cardiol Clin       Date:  2014-10-23       Impact factor: 2.213

5.  Cardiac workup of ischemic stroke.

Authors:  Xavier Ustrell; Anna Pellisé
Journal:  Curr Cardiol Rev       Date:  2010-08

6.  Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.

Authors:  W T Longstreth; Richard A Kronmal; John L P Thompson; Robert H Christenson; Steven R Levine; Rebecca Gross; Robin L Brey; Richard Buchsbaum; Mitchell S V Elkind; David L Tirschwell; Stephen L Seliger; J P Mohr; Christopher R deFilippi
Journal:  Stroke       Date:  2013-01-22       Impact factor: 7.914

7.  Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--the Find-AF study.

Authors:  Rolf Wachter; Rosine Lahno; Beatrice Haase; Mark Weber-Krüger; Joachim Seegers; Frank Edelmann; Janin Wohlfahrt; Götz Gelbrich; Anke Görlitz; Pawel Kermer; Dirk Vollmann; Gerd Hasenfuß; Klaus Gröschel; Raoul Stahrenberg
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

Review 8.  Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke.

Authors:  István Szegedi; László Szapáry; Péter Csécsei; Zoltán Csanádi; László Csiba
Journal:  Biomed Res Int       Date:  2017-07-13       Impact factor: 3.411

Review 9.  Cardioembolic stroke diagnosis using blood biomarkers.

Authors:  Victor Llombart; Teresa Garcia-Berrocoso; Alejandro Bustamante; Israel Fernandez-Cadenas; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2013-11

10.  A bioclinical pattern for the early diagnosis of cardioembolic stroke.

Authors:  Bruno Zecca; Clara Mandelli; Alberto Maino; Chiara Casiraghi; Giovanbattista Bolla; Dario Consonni; Paola Santalucia; Giuseppe Torgano
Journal:  Emerg Med Int       Date:  2014-03-05       Impact factor: 1.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.